ChemBriefGSK Boosts Oncology Rebuild with $11 Billion Nuvalent Deal
GlaxoSmithKline agreed to acquire Nuvalent for approximately $11 billion to expand its oncology pipeline with two late-stage lung cancer treatments. The move aims to counter patent cliffs on HIV drugs
reuters · 2026-06-10 23:04